Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.

Andrews CD, Bernard LS, Poon AY, Mohri H, Gettie N, Spreen WR, Gettie A, Russell-Lodrigue K, Blanchard J, Hong Z, Ho DD, Markowitz M.

AIDS. 2017 Feb 20;31(4):461-467. doi: 10.1097/QAD.0000000000001343.

PMID:
27902508
2.

Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.

Naggie S, Holland DP, Sulkowski MS, Thomas DL.

Clin Infect Dis. 2017 Jan 1;64(1):92-99. Epub 2016 Sep 28.

PMID:
27682067
3.

Prescription of Non-Occupational Post-Exposure HIV Prophylaxis by Emergency Physicians: An Analysis on Accuracy of Prescription and Compliance.

Malinverni S, Libois A, Gennotte AF, La Morté C, Mols P.

PLoS One. 2016 Apr 12;11(4):e0153021. doi: 10.1371/journal.pone.0153021. eCollection 2016.

4.

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Halper-Stromberg A, Nussenzweig MC.

J Clin Invest. 2016 Feb;126(2):415-23. doi: 10.1172/JCI80561. Epub 2016 Jan 11. Review.

5.

An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

De Clercq E.

Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 2. Review. No abstract available.

6.

Nondaily preexposure prophylaxis for HIV prevention.

Anderson PL, García-Lerma JG, Heneine W.

Curr Opin HIV AIDS. 2016 Jan;11(1):94-101. doi: 10.1097/COH.0000000000000213. Review.

7.

Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?

Dezzutti CS.

J Int AIDS Soc. 2015 Nov 2;18:20301. doi: 10.7448/IAS.18.1.20301. eCollection 2015. Review.

8.

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Nelson AG, Zhang X, Ganapathi U, Szekely Z, Flexner CW, Owen A, Sinko PJ.

J Control Release. 2015 Dec 10;219:669-80. doi: 10.1016/j.jconrel.2015.08.042. Epub 2015 Aug 24. Review.

9.

The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.

Jain S, Krakower DS, Mayer KH.

Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S200-4. doi: 10.1093/cid/civ094.

10.

Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery.

Doblecki-Lewis S, Cohen S, Liu A.

Curr Treat Options Infect Dis. 2015 Jun;7(2):101-112.

11.

Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men.

Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ.

Open Forum Infect Dis. 2015 Jan 1;2(1):ofu114. doi: 10.1093/ofid/ofu114. eCollection 2015 Jan.

12.

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.

Massud I, Martin A, Dinh C, Mitchell J, Jenkins L, Heneine W, Pau CP, García-Lerma JG.

J Antimicrob Chemother. 2015 May;70(5):1473-81. doi: 10.1093/jac/dku556. Epub 2015 Jan 27.

13.

Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis.

Krakower DS, Jain S, Mayer KH.

Curr HIV/AIDS Rep. 2015 Mar;12(1):127-38. doi: 10.1007/s11904-014-0253-5. Review.

14.

Post-exposure prophylaxis use and recurrent exposure to HIV among men who have sex with men who use crystal methamphetamine.

Oldenburg CE, Jain S, Mayer KH, Mimiaga MJ.

Drug Alcohol Depend. 2015 Jan 1;146:75-80. doi: 10.1016/j.drugalcdep.2014.11.010. Epub 2014 Nov 26.

15.

Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.

Jain S, Oldenburg CE, Mimiaga MJ, Mayer KH.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):97-101. doi: 10.1097/QAI.0000000000000403.

16.

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C; Partners PrEP Study Team.

Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.

17.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC.

Cell. 2014 Aug 28;158(5):989-999. doi: 10.1016/j.cell.2014.07.043. Epub 2014 Aug 14.

18.

Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.

Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DI, Lewis MG, Hattersley J, Li B, Hesselgesser J, Geleziunas R, Robb ML, Kim JH, Michael NL, Barouch DH.

Nature. 2014 Aug 7;512(7512):74-7. doi: 10.1038/nature13594. Epub 2014 Jul 20.

19.

Biomedical prevention: state of the science.

McCormack SM, Gafos M, Desai M, Cohen MS.

Clin Infect Dis. 2014 Jul;59 Suppl 1:S41-6. doi: 10.1093/cid/ciu297.

20.

Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review.

Jain S, Mayer KH.

AIDS. 2014 Jul 17;28(11):1545-54. doi: 10.1097/QAD.0000000000000301. Review.

Supplemental Content

Support Center